TG Therapeutics, Inc. has seen rapid enrolment of ENHANCE study, which could allow simplified dosing regime of IV Briumvi.
The study warns that failure to act risks normalizing a creative economy defined by exploitation, invisibility, and ...
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with ...
Whether infection of cells by individual virions occurs randomly or if there is some form (s) of competition or cooperativity between individual virions remains largely unknown for most virus-cell ...
The financial arrangement for the global Phase III program in common warts, where by Verrica and Torii split the cost of the program with the first $40 million funded by Torii has unlocked the ...
Q2 2026 Earnings Call Transcript November 10, 2025 Beyond Air, Inc. misses on earnings expectations. Reported EPS is $-1.25 ...
Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including ...
Chandigarh: Holding a Ludhiana-based hospital and a urologist and transplant surgeon liable for negligence, the State ...
On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...
Q3 2025 Earnings Call Transcript November 12, 2025 CorMedix Inc. beats earnings expectations. Reported EPS is $1259.23, ...
FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...
Operator: Good morning, and welcome to the ImmuCell Corporation Reports Third Quarter ended September 30, 2025, Unaudited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback